HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Puzzle: Measuring How DSHEA Fits For Supplement Industry Oversight

Executive Summary

FDA says it has "only received about 1,200 NDI notifications" in 25 years under DSHEA as US VMS market has grown from around $4b and 4,000 products to more than $40bn with 80,000 or more products. In interviews on potential changes agency may attempt to bring to its regulatory oversight, attorneys noted NDI notifications are among problems for both industry and FDA.

Advertisement

Related Content

Modernizing FDA's Supplement Industry Regulation Mapped Out In Five-Point Plan
FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence
Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry

Topics

Advertisement
UsernamePublicRestriction

Register

RS148715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel